Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it will invest in additional bioconjugation capabilities in Visp (CH). The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure to the existing bioconjugation facility in Visp (CH) for launch and commercial supply.

Lonza是制药、生物技术和营养保健市场的全球开发和制造合作伙伴，今天宣布将在Visp（CH）投资额外的生物缀合能力。扩建将在Visp（CH）现有的生物缀合设施的基础上增加两个多用途1200L制造套件和制造相关基础设施，用于发射和商业供应。

The new capacity will generate approximately 200 new jobs and is expected to be operational from 2028.The new suites will occupy approximately 2,000m2 and double Lonza’s multipurpose capacity for the launch and commercial supply of bioconjugates. The flexible multi-customer suites are designed to run the increasingly complex and variable processes needed to manufacture antibody-drug conjugates (ADCs) and other bioconjugates maturing through the drug pipeline.The additional bioconjugation suites will support the growth of Lonza’s leading bioconjugation offering, spanning manufacturing for early phase clinical development, large-scale manufacture for launch and commercial supply, and will include drug product filling capability.

新产能将产生约200个新工作岗位，预计从2028年开始运营。新套房将占地约2000平方米，是Lonza多功能生物缀合物发布和商业供应能力的两倍。灵活的多客户套件旨在运行制造抗体-药物缀合物（ADC）和通过药物管道成熟的其他生物缀合物所需的日益复杂和可变的过程。额外的生物缀合套件将支持Lonza领先的生物缀合产品的增长，涵盖早期临床开发的制造，上市和商业供应的大规模制造，并将包括药品填充能力。

This investment follows the recently announced customer-dedicated bioconjugation expansion in Visp (CH).Christian Morello, Vice President, Head of Bioconjugates, Lonza, commented: “We continue to see strong growth in the bioconjugates space as ADCs and other bioconjugated drugs increasingly progress towards commercialization.

这项投资是在Visp（CH）最近宣布的客户专用生物共轭扩张之后进行的。Lonza生物缀合物副总裁兼主管Christian Morello评论道：“随着ADC和其他生物缀合药物越来越走向商业化，我们继续看到生物缀合物领域的强劲增长。

This investment in our multipurpose commercial bioconjugation capacity addresses the growing market demand, enables us to support the growth of our customers and offers a flexible and integrated service for manufacturing bioconjugates.”As part of Lonza’s emission reduction strategy, the manufacturing suites follow sustainability design st.

对我们的多用途商业生物缀合能力的投资满足了不断增长的市场需求，使我们能够支持客户的增长，并为制造生物缀合物提供灵活而综合的服务。”作为Lonza减排战略的一部分，制造套件遵循可持续发展设计st。